Investigating how KRAS mutations drive cancer and how to inhibit them
Dissecting KRAS oncoprotein signaling with small molecule inhibitors
This study is looking at how certain changes in the KRAS gene help cancer grow and is testing new medicines that could turn off the faulty KRAS protein, which could lead to better treatments for people with KRAS-related cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10894720 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of KRAS mutations in cancer, particularly how these mutations keep the KRAS protein in an active state that promotes tumor growth. The team is exploring small molecule inhibitors that can selectively target and deactivate the mutated KRAS protein, which is crucial for developing effective cancer treatments. By studying the mechanisms of KRAS activation and the effects of these inhibitors, the research aims to provide insights into new therapeutic strategies for patients with KRAS-driven cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have KRAS mutations, such as lung cancer or pancreatic cancer.
Not a fit: Patients without KRAS mutations or those with cancers not driven by KRAS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target and inhibit KRAS mutations, improving outcomes for cancer patients.
How similar studies have performed: Other research has shown promising results with similar approaches targeting KRAS mutations, particularly with the development of specific inhibitors for the KRAS G12C mutation.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lito, Piro — Sloan-Kettering Inst Can Research
- Study coordinator: Lito, Piro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.